Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?

E-ISSN： 1873-4286|22|36|5558-5571

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.36, 2016-10, pp. : 5558-5571

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 3, 2011-03 ,pp. : 362-368

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy

Current Drug Discovery Technologies, Vol. 3, Iss. 1, 2006-03 ,pp. : 83-88

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 962-968

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 969-972

Bentham Science Publishers

Access to resources Recommend Favorite

Possible Involvement of Advanced Glycation End-Products (AGEs) in the Pathogenesis of Alzheimer's Disease

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 973-978

Bentham Science Publishers

Access to resources Recommend Favorite